Explore HIMS stock analysis with latest price, earnings, technicals, and forecast. Is HIMS stock a buy? Get balanced insights on valuation and outlook for everyday investors.

Introduction

Hims & Hers Health runs a telehealth platform. It sells prescription and over-the-counter health products like weight loss drugs directly to consumers. Investors watch HIMS stock now due to a key Novo Nordisk partnership for branded GLP-1 treatments. Broader market volatility in tech and healthcare stocks adds focus as growth slows in some areas.

Latest Stock Price & Trend

HIMS stock closed at $23.84 on March 12, 2026, using last market close data. It fell 7.88% that day from profit-taking after a multi-day surge. The 1-day performance showed a sharp drop, while 5-day trend stayed up over 40% from recent lows.

One-month trend pushed higher on partnership news, gaining from early February levels around $27. Three-month trend mixed with legal fears earlier, but rebounded strongly. Six-month trend bullish amid revenue jumps, up from sub-$20 levels. Year-to-date in 2026, HIMS stock rose over 20% despite pullbacks.

The 52-week high hit $70.43, low at $13.74. Overall trend looks bullish short-term but sideways after rally. This signals momentum for investors, yet caution on overbought risks.

Technical Analysis

Support levels sit near $22, a recent rebound point after lawsuit drop. Resistance looms at $25-$27, matching early 2026 highs. RSI at 31.8 shows lower-neutral, not oversold, hinting room to climb without exhaustion.

MACD trend leans bullish from recent crossovers on daily charts. The 50-day moving average hovers around $31, 200-day near $46—stock trades below both, signaling pullback in uptrend. No golden cross yet; watch for 50-day crossing above 200-day for stronger buy signal.

Trading volume spiked on partnership news, now cooling, which matters for confirming trends. These indicators help beginners spot entry points and avoid traps.​

Analyst Ratings & Price Targets

Analysts rate HIMS stock as Hold overall. From 16 firms, counts show 8 Buy, 6 Hold, 2 Sell. Average price target at $28.21, up 17.52% from $24 levels. Highest target $60 from BTIG, lowest around $20.

BTIG cut from $85 to $60 but kept positive on growth. This sentiment means caution after run-up, yet upside if execution holds. Investors use it to gauge Wall Street views.​

Insider Activity

Recent insider buying stayed low amid stock surge. No large buys noted in Q1 2026 filings. Selling picked up post-rally, with executives trimming shares.​

Trends show management holding steady, no panic sales. This implies quiet confidence, not red flags, as leaders stay invested.​

Valuation Analysis

Trailing P/E stands at 60.36 on 2025 earnings. Forward P/E lower at estimated 40x on growth. Price-to-Sales around 3.7x with $2.35B 2025 revenue. Revenue grew 59% YoY, EPS up sharply to positive $0.88 TTM.

Free cash flow improved to positive territory. Debt low, cash strong at $128M net income backing. Vs. peers like Zoom, HIMS trades cheaper on sales growth; Microsoft multiples higher on scale.​

HIMS stock appears fairly valued, not overpriced for telehealth expansion.​

Recent Earnings & Catalysts

Q4 2025 revenue hit $2.35B, beating estimates. EPS came in at positive, driving net income to $128M. Forward guidance eyes more GLP-1 sales.​

Key catalysts include Novo Nordisk deal for Ozempic/Wegovy access, ending lawsuit fears. Eucalyptus acquisition boosts international reach in Australia, UK. Earnings sparked initial rally, then profit-taking.

Bullish Case

HIMS stock benefits from GLP-1 demand boom. Novo partnership opens branded drug sales, scaling subscribers fast. Revenue growth catalysts like international expansion add markets.​

Tech platform cuts costs, improves margins over time. Subscriber model drives steady cash flow.​

Bearish Case

Competition heats from telehealth rivals and big pharma. Slowing GLP-1 hype could hit growth. Margin pressures rise if drug costs climb.​

Regulatory scrutiny on compounded drugs lingers. Economic slowdowns cut elective health spending.​

Market Sentiment & Investor Psychology

Short interest low at under 10%, down recently. Options show more calls than puts post-partnership. Institutional ownership up to 60%, adding shares.

Retail chases momentum, value players wait for dip. Sentiment tilts optimistic on catalysts.​

Short-Term Outlook

Technicals point to consolidation near $22-$25. Volume drop suggests pause after rally. Momentum favors upside if support holds, but watch broader market dips.​

Medium to Long-Term Outlook

Strong business model in telehealth grows with weight loss trends. Industry expands at 20%+ CAGR. Competitive edge via partnerships.​

Financial health solid with cash flow turning positive. Long-term investors should hold or accumulate on dips for HIMS forecast gains.​

FAQ

Is HIMS stock a buy right now?
Hold for now; wait for dip to $22 support. Growth intact but post-rally caution rules.​

What is the HIMS stock price target?
Average $28.21, high $60. Ties to revenue execution.​

What are major risks for HIMS stock?
Competition, regulation, growth slowdowns.​

When are HIMS earnings next?
May 4, 2026.​

HIMS stock forecast for 2026?
$25-$30 range if catalysts deliver.​

Suggestion

Compare with [Opendoor stock analysis].
See [Microsoft stock forecast].
Read [tech sector valuation guide].

Conclusion

HIMS stock merits Watchlist status. Balanced growth via partnerships offsets risks like competition. Hold if owned; buy dips for long-term HIMS outlook.

Disclaimer: This article is for informational purposes only and not financial advice.